Lutein for alleviating early high mortality and
brain pathology after experimental stroke in a genetic type I diabetic mouse model: abridged secondary publication
AKW Lai1, DTC Ng1, BKC Tam1, FKC Fung1, SK Chung2, ACY Lo1
1Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong
2School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong
1. Hyperglycaemia plays an important role in the
rapid exacerbation of stroke by compromising
blood vessel integrity and increasing
haemorrhagic transformation, resulting in
extensive inflammation and high mortality.
2. These exacerbations are partially contributed by VEGF up-regulation, which has deleterious effects via triggering robust inflammation and vascular hyperpermeability.
3. After 0.5 hour of ischaemia, Ins2Akita/+ mice displayed a delayed but significant development of infarct.
4. Lutein treatment reduced neurological deficits (after 0.5 hour of ischaemia) and mortality rate (after 2 hours of ischaemia).
5. Lutein is a potential treatment for stroke patients with type 1 diabetes.
2. These exacerbations are partially contributed by VEGF up-regulation, which has deleterious effects via triggering robust inflammation and vascular hyperpermeability.
3. After 0.5 hour of ischaemia, Ins2Akita/+ mice displayed a delayed but significant development of infarct.
4. Lutein treatment reduced neurological deficits (after 0.5 hour of ischaemia) and mortality rate (after 2 hours of ischaemia).
5. Lutein is a potential treatment for stroke patients with type 1 diabetes.